At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
09637 ALEBUND-B
Closed 08-06 16:08:34
32.680
-0.520
-1.57%
High33.800Low31.160Vol278.42K
Open32.980D1 Closing33.200Amplitude7.95%
Mkt Cap11.37BTradable Cap7.71BTotal Shares348.00M
T/O9.05MT/O Rate0.12%Tradable Shares236.00M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.
Alebund Pharma Expects H1 Revenue RMB 103 Million-RMB 106 Million, up About 750%-775%
Reuters  ·  16:39
Alebund Pharma Expects H1 Revenue RMB 103 Million-RMB 106 Million, up About 750%-775%
Alebund Pharmaceuticals Completes 8.51 Million-Share Over-Allotment, Total Issued Capital Rises to 348.37 Million
Bulletin Express  ·  08-05 16:52
Alebund Pharmaceuticals Completes 8.51 Million-Share Over-Allotment, Total Issued Capital Rises to 348.37 Million
Hong Kong Stock Moves: ALEBUND-B Rises Over 6% After Global Phase IIb Trial Milestone for AP306
Stock News  ·  08-03
Hong Kong Stock Moves: ALEBUND-B Rises Over 6% After Global Phase IIb Trial Milestone for AP306
Alebund Pharmaceuticals Publishes July 2026 Articles of Association, Confirms RMB348.37 Million Capital and Governance Framework
Bulletin Express  ·  07-29
Alebund Pharmaceuticals Publishes July 2026 Articles of Association, Confirms RMB348.37 Million Capital and Governance Framework
Alebund Pharmaceuticals Amends Bylaws to Update Registered Capital to RMB 348.37 Million
Reuters  ·  07-29
Alebund Pharmaceuticals Amends Bylaws to Update Registered Capital to RMB 348.37 Million
ALEBUND-B (09637) Issued 8.51 Million Shares Following Full Exercise of Over-Allotment Option
Stock News  ·  07-29
ALEBUND-B (09637) Issued 8.51 Million Shares Following Full Exercise of Over-Allotment Option
Alebund Pharma Nets HK$185 Million From Full Exercise of IPO Over-Allotment Option
MT Newswires Live  ·  07-27
Alebund Pharma Nets HK$185 Million From Full Exercise of IPO Over-Allotment Option
Alebund Pharmaceuticals Says no Market Purchases Made for Price Stabilization During IPO Stabilisation Period
Reuters  ·  07-24
Alebund Pharmaceuticals Says no Market Purchases Made for Price Stabilization During IPO Stabilisation Period
Tencent Holdings Boosts Stake in ALEBUND-B with 238,500 Share Purchase
Stock News  ·  07-23
Tencent Holdings Boosts Stake in ALEBUND-B with 238,500 Share Purchase
ALEBUND-B: Tencent Holdings Limited Acquires Shares, Long Position Rises to 10.09%
HK Disclosure  ·  07-23
ALEBUND-B: Tencent Holdings Limited Acquires Shares, Long Position Rises to 10.09%
Alebund Pharma adopts electronic dissemination of corporate communications under HKEX paperless regime
Bulletin Express  ·  07-22
Alebund Pharma adopts electronic dissemination of corporate communications under HKEX paperless regime
Alebund Pharmaceuticals Adopts Fully Electronic Dissemination of Corporate Communications
Bulletin Express  ·  07-22
Alebund Pharmaceuticals Adopts Fully Electronic Dissemination of Corporate Communications
Alebund Pharma Doses First Patient in Global Phase 2b Hyperphosphatemia Trial
MT Newswires Live  ·  07-22
Alebund Pharma Doses First Patient in Global Phase 2b Hyperphosphatemia Trial
ALEBUND-B Advances Global Phase IIb Trial for Hyperphosphatemia Treatment with First Patient Dosed
Stock News  ·  07-21
ALEBUND-B Advances Global Phase IIb Trial for Hyperphosphatemia Treatment with First Patient Dosed
Alebund Pharmaceuticals, R1 Therapeutics Partner on Global Development of AP306 Outside Greater China
Reuters  ·  07-21
Alebund Pharmaceuticals, R1 Therapeutics Partner on Global Development of AP306 Outside Greater China
Alebund Pharmaceuticals Announces First Participant Randomized and Dosed in Global Phase Iib Multi-regional Clinical Trial of AP306 for Hyperphosphatemia
THOMSON REUTERS  ·  07-21
Alebund Pharmaceuticals Announces First Participant Randomized and Dosed in Global Phase Iib Multi-regional Clinical Trial of AP306 for Hyperphosphatemia
ALEBUND-B Shares Surge Over 11% in Morning Session Following Major Institutional Buys; AP301 Nears NDA Submission
Stock News  ·  07-15
ALEBUND-B Shares Surge Over 11% in Morning Session Following Major Institutional Buys; AP301 Nears NDA Submission
Movement Alert｜Alebund Pharmaceuticals-B Falls 7.56% in Regular Trading, Post-IPO Volatile Pattern Persists as Stock Retreats Over 40% From High
Market Focus  ·  07-13
Movement Alert｜Alebund Pharmaceuticals-B Falls 7.56% in Regular Trading, Post-IPO Volatile Pattern Persists as Stock Retreats Over 40% From High
Movement Alert｜Alebund Pharmaceuticals-B Declines 5.26% in Regular Trading, Post-IPO Volatile Pattern Extends as Short-Term Profit-Taking Continues
Market Focus  ·  07-10
Movement Alert｜Alebund Pharmaceuticals-B Declines 5.26% in Regular Trading, Post-IPO Volatile Pattern Extends as Short-Term Profit-Taking Continues
Movement Alert｜Alebund Pharmaceuticals-B Falls 5.4% in Regular Trading, Short-Term Profit-Taking After Prior Session Surge
Market Focus  ·  07-09
Movement Alert｜Alebund Pharmaceuticals-B Falls 5.4% in Regular Trading, Short-Term Profit-Taking After Prior Session Surge

Introduction

Company Name.
ALEBUND-B
Affiliated Markets:
SEHK
Listing Date:
--
Main Business:
Alebund Pharmaceuticals (Jiangsu) Ltd is a China-based company principally engaged in biopharmaceutical business. The Company’s product portfolio in clinical and preclinical stages consists of one core product AP301 and other product candidates, including one late-clinical-stage product candidate AP306, one early-clinical-stage product candidate (AP303), and four preclinical product candidates (AP308, AP304, AP305, and AP307). The Company mainly operates its businesses in the domestic market and overseas markets.
Issue price:
--